Literature DB >> 7451988

Binding of C1q and complement activation by vascular endothelium.

E Linder.   

Abstract

Exposure of intermediate filaments of cultured cells to serum leads to antibody-independent binding of complement (C) component C1q, C4, and C3. The apparent C-activating property of cytoskeletal intermediate filaments was examined on a tissue level in The present study by using frozen sections of human kidney and term placentas as targets. The assay used fresh human serum or isolated C1q as sources of C and the bound C components were demonstrated by fluorescent conjugates against C1q, C4, and C3. A consistent finding was that the endothelium of vessel walls had the capacity to bind both C1q and C components C4 and C3. Less intense binding of C to vascular smooth muscle was noted. Binding of C1q was very rapid, taking place within 10 sec. Subsequently, accumulation of C4 and C3 was seen. Subsequently, accumulation of C4 and C3 was seen. Upon prolonged incubation, a decrease in demonstrable C1q and C4 was observed. Unfixed vascular endothelium bound both isolated C1q and C1q of EDTA- or enzyme inhibitor-treated serum. However, if unfixed, the binding structures appeared to be destroyed in the process of C activation. They were also readily destroyed by trypsin. The described observations seem to suggest a possible mechanism whereby C components may become deposited in vessel walls independently of antibodies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7451988

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  The cytoskeleton and its importance as a mediator of inflammation.

Authors:  K R Rogers; C J Morris; D R Blake
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

2.  Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.

Authors:  H E Feucht; E Felber; M J Gokel; G Hillebrand; U Nattermann; C Brockmeyer; E Held; G Riethmüller; W Land; E Albert
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

3.  Complement-mediated binding of monocytes to intermediate filaments in vitro.

Authors:  E Linder; H Helin; C M Chang; T S Edgington
Journal:  Am J Pathol       Date:  1983-09       Impact factor: 4.307

Review 4.  Immunologically mediated lesions of kidney tubules and interstitium in laboratory animals and in man.

Authors:  J R Brentjens; B Noble; G A Andres
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells.

Authors:  G K Hansson; G A Starkebaum; E P Benditt; S M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

6.  Isolation of metabolically active endothelial cells in high yield from bovine cavernous bodies. A model for functional studies on freshly isolated microvascular endothelial cells.

Authors:  A Dobrina; M R Soranzo; F Rossi
Journal:  Cell Tissue Res       Date:  1983       Impact factor: 5.249

7.  Immunological studies of human placentae: complement components in pre-eclamptic chorionic villi.

Authors:  D Sinha; M Wells; W P Faulk
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

8.  A new serological reaction in patients with polymyalgia rheumatica and/or giant cell (temporal) arteritis: deposition of complement C4 and C3 components on rat kidney structures detected by indirect immunofluorescence.

Authors:  P Vaith; D Maas; G von Stackelberg; H H Peter
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

9.  The thickening of basement membrane in synovial capillaries in rheumatoid arthritis.

Authors:  T Matsubara; M Velvart; B F Odermatt; M A Spycher; J R Rüttner; K Fehr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

10.  Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  D B Cines; A P Lyss; M Reeber; M Bina; R J DeHoratius
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.